C. The Antineutrophil Cytoplasmic Antibody-Associated Vasculitides: Wegener’s Granulomatosis, Microscopic Polyangiitis, and the Churg-Strauss Syndrome
  • John H. Stone


  • Many patients with Wegener’s granulomatosis (WG), microscopic polyangiitis (MPA), or the Churg-Strauss syndrome (CSS) have antineutrophil cytoplasmic antibodies (ANCA) within their serum.

  • As a result, these three disorders are termed the ANCA-associated vasculitides (AAV), even though not all patients with these conditions have ANCA.

  • Multiple antibodies may lead to positive immunofluorescence testing for ANCA in either perinuclear (PANCA) or cytoplasmic (C-ANCA) patterns. However, only antibodies to myeloperoxidase (MPO) and proteinase-3 (PR3) are associated with the AAV.

  • Wegener’s granulomatosis may be associated with destructive upper respiratory tract disease, including saddle-nose deformity, erosive sinusitis, and subglottic stenosis. The CSS is often associated with allergic rhinitis, nasal polyposis, or sinusitis, but is rarely associated with destructive lesions.

  • A host of ocular lesions may occur in the AAV, including episcleritis, scleritis, peripheral ulcerative keratitis, and orbital pseudotumor.

  • Lung disease is common in the AAV and ranges from asthma (in CSS) to nodular lesions with a tendency to cavitate (in WG) to interstitial lung disease (MPA) to alveolar hemorrhage (all forms of AAV).

  • Segmental, necrotizing glomerulonephritis commonly accompanies the AAV, particularly WG and MPA.

  • ■ Eosinophilia is the sine qua non of CSS.


Antineutrophil Cytoplasmic Antibody Subglottic Stenosis Strauss Syndrome Eosinophilic Gastroenteritis Chronic Eosinophilic Pneumonia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Godman G, Churg J. Wegener’s granulomatosis: pathology and review of the literature. Arch Pathol Lab Med 1954;58:533.Google Scholar
  2. 2.
    Van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet 1985;1:425–429.PubMedGoogle Scholar
  3. 3.
    Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988;318:1651–1657.PubMedCrossRefGoogle Scholar
  4. 4.
    Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 1990;33:1101–1107.PubMedCrossRefGoogle Scholar
  5. 5.
    Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990;33:1094–1100.PubMedCrossRefGoogle Scholar
  6. 6.
    Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122–1128.PubMedCrossRefGoogle Scholar
  7. 7.
    Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187–192.PubMedCrossRefGoogle Scholar
  8. 8.
    Watts RA, Carruthers DM, Scott DG. Epidemiology of systemic vasculitis: changing incidence or definition? Semin Arthritis Rheum 1995;25:28–34.PubMedCrossRefGoogle Scholar
  9. 9.
    Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener’s granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488–498.PubMedGoogle Scholar
  10. 10.
    Stone JH for the WGET Research Group. Limited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener’s granulomatosis etanercept trial. Arthritis Rheum 2003;48:2299–2309.CrossRefGoogle Scholar
  11. 11.
    Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies. Arthritis Rheum 1998;41:1521–1537.PubMedGoogle Scholar
  12. 12.
    Stone JH, Talor M, Stebbing J, et al. Test characteristics of immunofluorescence and ELISA tests in 856 consecutive patients with possible ANCA-associated conditions. Arthritis Care Res 2000;13:424–434.PubMedCrossRefGoogle Scholar
  13. 13.
    Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000;43:2025–2033.PubMedCrossRefGoogle Scholar
  14. 14.
    Finkielman JD, Merkel PA, Schroeder D, et al. Antineutrophil cytoplasmic antibodies against proteinase 3 do not predict disease relapses in Wegener’s granulomatosis. Ann Intern Med 2007, (in press).Google Scholar
  15. 15.
    Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110:955–963.PubMedCrossRefGoogle Scholar
  16. 16.
    Choi HK, Merkel PA, Walker AM, et al. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 2000;43:405–413.PubMedCrossRefGoogle Scholar
  17. 17.
    Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006;173:180–187.PubMedCrossRefGoogle Scholar
  18. 18.
    Wung PK, Stone JH. Therapeutics for Wegener’s granulomatosis. Nat Clin Pract Rheumatol 2006;2:192–200.PubMedCrossRefGoogle Scholar
  19. 19.
    WGET Research Group. Design of the Wegener’s Granulomatosis Etanercept Trial (WGET). Control Clin Trials 2002;23:450–468.CrossRefGoogle Scholar
  20. 20.
    Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36–44.PubMedCrossRefGoogle Scholar
  21. 21.
    Langford CA, Talar-Williams C, Barron KS, et al. A staged approach to the treatment of Wegener’s granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999;42:2666–2673.PubMedCrossRefGoogle Scholar
  22. 22.
    The WGET Research Group. Etanercept in addition to standard therapy in patients with Wegener’s granulomatosis. N Engl J Med 2005;352:351–361.CrossRefGoogle Scholar
  23. 23.
    Stone JH, Holbrook JT, Tibbs A, et al. Solid malignancies in the Wegener’s granulomatosis Etanercept trial. Arthritis Rheum 2006;54:1608–1618.PubMedCrossRefGoogle Scholar
  24. 24.
    Hoffman GS, Thomas-Golbanov CK, et al. Treatment of subglottic stenosis, due to Wegener’s granulomatosis, with intralesional corticosteroids and dilation. J Rheumatol 2003;30:1017–1021.PubMedGoogle Scholar
  25. 25.
    Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003;41:776–784.PubMedGoogle Scholar
  26. 26.
    Seo P, Min Y-I, Holbrook JT, et al. Damage from Wegener’s granulomatosis and its treatment: prospective data from the Wegener’s Granulomatosis Etanercept Trial. Arthritis Rheum 2005;52:2168–2178.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • John H. Stone
    • 1
    • 2
  1. 1.UpToDateBostonUSA
  2. 2.Massachusetts General HospitalBostonUSA

Personalised recommendations